Rwanda launches Africa’s first trial of long-acting malaria prevention injection
Originally published by News – Capital FM — Read the original article →
NAIROBI, Kenya, Nov 6-Rwanda has launched Africa’s first clinical trial of a long-acting injectable drug for malaria prevention, marking a potential shift in how the disease is prevented as drug resistance and climate change threaten progress against the mosquito-borne illness.
The Phase 1b trial, launched by Medicines for Malaria Venture (MMV) in partnership with Rwandan health research organisation Rinda Ubuzima, will assess the safety and tolerability of MMV371, an experimental drug designed to provide extended protection against malaria through a single injection.
The injectable could potentially protect recipients for an entire malaria season, reducing the need for frequent preventive medication if its safety and effectiveness are established.
